MeiraGTx and ZipBio Partner to Advance Gene Therapy for Geographic Atrophy

ZipBio and MeiraGTx have entered into an exclusive license agreement to advance a first-in-class AAV gene therapy for Geographic Atrophy. The deal leverages the strengths of both companies, combining MeiraGTx's expertise in vector design and clinical development with ZipBio's expertise in de novo-designed protein therapeutics using its COMPACT™ generative AI platform. The agreement includes upfront, milestone, and royalty payments, with financial terms not disclosed.